Pipeline dossier

NIH & clinical-trial pipeline signals for NOVARTIS AG (NVS)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for NVS, mapped to public ticker NVS (CIK 0001114448). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingNVS55% conf

NOVARTIS AG (NVS) — PHASE3 primary completion in ~160 days

Upstream (observed)
Clinical trial status (PHASE3) — Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVS55% conf

NOVARTIS AG (NVS) — PHASE1 primary completion 51 days ago (readout window)

Upstream (observed)
Clinical trial status (PHASE1) — Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

JSON API for this entity →